By PTI
NEW DELHI: Looking to ramp up supplies ahead of the opening of Covid-19 vaccination to all citizens over 18 years of age, the government has approved a payment of about Rs 4,500 crore as advance to vaccine makers like Serum Institute of India (SII) and Bharat Biotech against future supplies, sources said.
SII will supply 200 million doses and Bharat Biotech is to supply another 90 million doses to the government by July at a pre-agreed rate of Rs 150 per dose.
Sources said the finance ministry has relaxed rules to allow advance payment without bank guarantee to help the vaccine makers ramp up production.
SII will get Rs 3,000 crore in advance and Bharat Biotech about Rs 1,500 crore.
Earlier this month, SII CEO Adar Poonawalla had said that the company would require around Rs 3,000 crore to ramp up production capacity for making vaccines for COVID-19.
Meanwhile, the government on Monday allowed citizens over the age of 18 years to receive Covid-19 vaccination from May 1 as it seeks to control the rapid spread of the virus.
ALSO READ | COVID clinical symptoms, CT scans/X-rays should be used to rule out false negatives: Experts
Under the third phase of its vaccination strategy, manufacturers will be required to supply 50 per cent of their monthly doses to the government and the rest to state governments or the open market.
Vaccination will continue as before in the government of India vaccination centres free of cost for the eligible population — healthcare and frontline workers and all people above 45 years of age.
Latest data showed that over 2.59 lakh coronavirus infections pushed overall cases in India to more than 1.53 crore, making the country the second-worst affected nation after the US, which has reported more than 3.1 crore infections.
India’s deaths from COVID-19 rose by a record 1,761 to over 1.8 lakh.
ALSO READ | Remdesivir not magic bullet, does not reduce mortality against COVID-19, say health experts
Under the third phase of the national vaccination drive commencing next month, the vaccine manufacturers would supply 50 per cent of their monthly Central Drugs Laboratory (CDL) released doses to the central government and would be free to supply the remaining 50 per cent doses to state governments and in the open market.
Manufacturers would have to make an advance declaration of the price for the 50 per cent supply that would be available to the state governments and in the open market before May 1, 2021, an official statement by the Union Health Ministry said.
Based on this price, state governments, private hospitals, industrial establishments, etc., would be able to procure vaccine doses from the manufacturers.
Private hospitals would have to procure their supplies of COVID-19 vaccine exclusively from the 50 per cent supply earmarked for entities other than those coming through the central government channel.
“The private vaccination providers would need to transparently declare their self-set vaccination price and the eligibility through this channel would be opened up to all adults, that is everyone above the age of 18,” the statement added.
Vaccination will continue as before in the government of India vaccination centres free of cost to the eligible population — healthcare and frontline workers and all people above 45 years of age.
ALSO READ | Johnson & Johnson seeks permission for phase-III trial of its COVID vaccine in India, import licence
The Health Ministry said the important decision to allow vaccination to everyone above the age of 18 from May 1 was taken in a meeting chaired by Prime Minister Narendra Modi.
“Prime Minister said that the government has been working hard for over a year to ensure that maximum numbers of Indians are able to get the vaccine in the shortest possible of time.
He added that India is vaccinating people at world record pace and we will continue this with even greater momentum,” it added.
The decisions came as India’s total tally of COVID-19 cases crossed the grim milestone of 1.5 crore with a record single-day rise of 2,73,810 infections and the death toll increased to 1,78,769 with a record 1,619 daily new fatalities, according to data updated Monday morning.
Also, the cumulative vaccine doses administered across the country has reached 12,38,52,566, according to the government data.
ALSO READ | ‘Second Covid-19 wave in Delhi likely to peak within a week’: Experts predict grim situation for national capital
All vaccinations will be under the Liberalised and Accelerated Phase 3 Strategy of the National COVID-19 Vaccination programme and will have to follow all protocol such as being captured on CoWIN platform, linked to AEFI reporting and all other prescribed norms.
Stocks and price per vaccination applicable in all vaccination centres will also have to be reported real-time.
The division of vaccine supply 50 per cent to the Government of India and 50 per cent to other channels would be applicable uniformly across for all vaccines manufactured in the country.
“However, Government of India will allow the imported fully ready to use vaccines to be entirely utilized in the other than government of India channel.
“The government of India from its share will allocate vaccines to states and UTs based on the criteria of extent of infection (number of active COVID cases) and performance (speed of administration). Wastage of vaccine will also be considered in this criteria and will affect the criteria negatively. Based on the above criteria, state-wise quota would be decided and communicated to the states adequately in advance,” the statement stated.
Second dose of all existing priority groups — healthcare workers, frontline workers and population above 45 years, wherever it has become due, would be given priority, for which a specific and focused strategy would be communicated to all stakeholders.
The strategy will be reviewed from time to time.
The ministry, in its statement, stated that India’s approach has been built on scientific and epidemiological pillars, guided by global best practices, SoPs of WHO as well as India’s foremost experts in the National Expert Group on Vaccine Administration for Covid-19 (NEGVAC).
India has been following a dynamic mapping model based on availability of vaccines and coverage of vulnerable priority groups to take decisions of when to open up vaccinations to other age-groups.
A good amount of coverage of vulnerable groups is expected by April 30.
ALSO READ | ‘Non-serious people questioning India’: Jaishankar rejects criticism over export of COVID-19 vaccines
Phase-I of the National COVID-18 Vaccination Strategy was launched on January 16, prioritizing protection for healthcare workers and frontline workers.
Phase-II was initiated from March 1, focusing on protecting most vulnerable i.e. all people above 45 years of age, accounting for more than 80 per cent COVID-19 mortality in the country.
The private sector was also roped in to augment capacity.
The strength of India’s private sector vaccine manufacturing capability has been strategically empowered through unprecedented decisive steps, from facilitating public-private collaborative research, trials and product development, to targeted public grants and far-reaching governance reforms in India’s regulatory system.
On PM Modi’s instructions, India is in regular touch with each manufacturer, including having sent multiple inter-ministerial teams on site, to understand each one’s requirements and provide proactive and customized support in the form of grants, advance payments, more sites for production, etc., to ramp up vaccine production, the ministry said.
This has resulted in emergency use authorisation being granted to two vaccines — Bharat Biotech’s Covaxin and Covishield being manufactured by Serum Institute of India — and a third vaccine (Sputnik V) that is presently being manufactured abroad and will eventually be manufactured in India, the statement said.
